Related references
Note: Only part of the references are listed.Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients
Nora Liebers et al.
BLOOD (2022)
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
Yair Herishanu et al.
BLOOD (2022)
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy
Stephen Booth et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Christina Y. Lee et al.
CANCER DISCOVERY (2022)
High Frequency of SARS-CoV-2 RNAemia and Association With Severe Disease
Catherine A. Hogan et al.
CLINICAL INFECTIOUS DISEASES (2021)
Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient
Ji Hoon Baang et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
Cathrine Axfors et al.
BMC INFECTIOUS DISEASES (2021)
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study
Luna Colagrossi et al.
BMC INFECTIOUS DISEASES (2021)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Nicole M. Kuderer et al.
LANCET (2020)
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Jason D. Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma
Hajime Yasuda et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Roch Houot et al.
EUROPEAN JOURNAL OF CANCER (2020)
Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma
Ayse Karatas et al.
TRANSFUSION AND APHERESIS SCIENCE (2020)
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
Abi Vijenthira et al.
BLOOD (2020)
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
Bina Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer
Teresa Aydillo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19
Jesus F. Bermejo-Martin et al.
CRITICAL CARE (2020)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al.
LANCET (2011)
Treatment with convalescent plasma for influenza A (H5N1) infection
Boping Zhou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)